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Abstract
Objective:  To  characterize  varicella  zoster  virus-related  deaths  and  hospitalizations  in  Brazil
before universal  vaccination  with  the  tetravalent  (measles,  mumps,  rubella,  and  varicella)
vaccine, attempting  to  collect  baseline  data  on  varicella  morbidity  and  mortality  in  order  to
evaluate  the  impact  of  the  varicella  vaccination  program.
Methods:  Varicella-associated  mortality  data  were  evaluated  between  1996  and  2011  and  vari-
cella zoster  virus-associated  hospitalizations  between  1998  and  2013.  Data  were  gathered  from
the Informatics  Department  of  the  Uniﬁed  Health  System,  considering  the  International  Classi-
ﬁcation of  Diseases,  10th  Revision,  code  B01.  All  age  groups  were  assessed.  Varicella-speciﬁc
mortality  rates  were  calculated  and  seasonality  of  varicella-zoster  virus-associated  hospitaliza-
tions was  described.
Results:  There  were  2334  varicella  deaths  between  1996  and  2011,  19.3%  in  infants  aged  less
than 1  year  and  36%  in  children  from  1  to  4  years.  In  infants  under  1  year,  varicella  mortality
rates reached  3.2/100,000/year.  In  children  aged  1--4  years,  varicella  mortality  rates  reach
1.64/100,000/year.  Average  annual  mortality  rates  for  varicella  in  Brazil  are  0.88/100,000  in
infants under  1  year  and  0.40/100,000  in  children  aged  1--4  years.  The  total  number  of  hospital-
izations associated  with  varicella  zoster  virus  was  62,246  from  2008  to  2013.  Varicella-associated
hospitalizations  have  a  seasonal  distribution  in  children,  peaking  in  November.  In  the  elderly,
monthly averages  of  herpes  zoster-associated  hospitalizations  present  no  signiﬁcant  seasonal
variation.
 Please cite this article as: Martino Mota A, Carvalho-Costa FA. Varicella zoster virus related deaths and hospitalizations before the
introduction of universal vaccination with the tetraviral vaccine. J Pediatr (Rio J). 2016;92:361--6.
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Conclusions:  Varicella  is  associated,  in  the  pre-vaccine  period,  to  signiﬁcant  morbidity  and
mortality  in  Brazil.  The  universal  vaccination  program  is  expected  to  decrease  the  disease
burden from  varicella.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Óbitos  e  internac¸ões  relacionados  ao  vírus  varicela-zoster  antes  da  introduc¸ão  da
vacinac¸ão  universal  com  a  vacina  tetravalente
Resumo
Objetivo:  Caracterizar  os  óbitos  e  internac¸ões  relacionados  ao  vírus  varicela-zoster  no  Brasil
antes da  vacinac¸ão  universal  com  a  vacina  tetravalente  (sarampo,  caxumba,  rubéola  e  varicela),
tentando coletar  dados  de  referência  sobre  a  morbidez  e  mortalidade  por  varicela,  para  avaliar
o impacto  do  programa  de  vacinac¸ão  contra  a  varicela.
Métodos:  Os  dados  de  mortalidade  associada  à  varicela  foram  avaliados  entre  1996  e  2011  e  as
internac¸ões associadas  ao  vírus  varicela-zoster,  entre  1998  e  2013.  Os  dados  foram  coletados
do Departamento  de  Informática  do  Sistema  Uniﬁcado  de  Saúde,  considerando  a  Classiﬁcac¸ão
Internacional  de  Doenc¸as,  10a Revisão,  código  B01.  Todas  as  faixas  etárias  foram  avaliadas.
Foram calculadas  as  taxas  de  mortalidade  especíﬁcas  por  varicela  e  foi  descrita  a  sazonalidade
das internac¸ões  associadas  ao  vírus  varicela-zoster.
Resultados:  Houve  2.334  óbitos  por  varicela  entre  1996  e  2011,  19,3%  em  neonatos  com  menos
de 1  ano  e  36%  em  crianc¸as  de  1  a  4  anos.  Em  neonatos  com  menos  de  1  ano,  as  taxas  de
mortalidade  por  varicela  atingiram  3,2/100.000/ano.  Em  crianc¸as  de  1--4  anos  de  idade,  as
taxas de  mortalidade  por  varicela  atingem  1,64/100.000/ano.  As  taxas  de  mortalidade  anu-
ais médias  por  varicela  no  Brasil  são  de  0,88/100.000  em  neonatos  com  menos  de  1  ano  de
idade e  0,40/100.000  em  crianc¸as  de  1  a  4  anos  de  idade.  O  número  total  de  internac¸ões  asso-
ciadas ao  vírus  varicela-zoster  foi  de  62.246  de  2008  a  2013.  As  internac¸ões  relacionadas  à
varicela apresentaram  distribuic¸ão  sazonal  em  crianc¸as,  com  pico  em  novembro.  Em  idosos,  as
médias mensais  de  internac¸ões  associadas  ao  herpes  zoster  não  apresentam  variac¸ão  sazonal
signiﬁcativa.
Conclusões:  A  varicela  está  associada  a  morbidez  e  mortalidade  signiﬁcativas  no  período  pré-
vacinac¸ão no  Brasil.  O  programa  de  vacinac¸ão  universal  deve  diminuir  a  carga  de  doenc¸a  da
varicela.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
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aricella  (chickenpox)  is  an  acute,  exanthematic  and  conta-
ious  infectious  disease  that  occurs  primarily  in  childhood.1
t  is  caused  by  varicella  zoster  virus  (VZV),  an  alpha  herpes
irus  belonging  to  the  herpesviridae  family.2--4 After  resolu-
ion  of  chickenpox,  VZV  remains  latent  in  dorsal  root  spinal
anglia  and  reactivation  can  arise  at  any  stage  of  life,  more
requently  at  an  older  age,  causing  herpes  zoster.2,3,5--7
Although  it  is  generally  considered  a  mild  childhood
isease,  varicella  can  be  severe  in  children,  adults,  and
mmunocompromised  individuals8 due  to  risk  of  viral  dis-
emination  to  internal  organs,  such  as  lungs,  liver,  brain,
eart,  and  kidneys.  The  most  frequent  complications  of  vari-
ella  are  secondary  bacterial  infections  caused  by  Group
 -hemolyticus  Streptococcus  or  Staphylococcus  aureus,
sually  affecting  the  skin  and  soft  tissues.  Invasive  bacte-
ial  infections  such  as  pneumonia,  arthritis,  osteomyelitis,
epsis,  and  necrotizing  fasciitis  may  be  fatal.1 Neurologi-
al  complications  such  as  cerebellar  ataxia,  encephalitis,
eningitis,  and  vasculitis  can  also  occur.9
a
o
tThe  live  attenuated  vaccine  against  varicella  was  for-
ulated  in  Japan  in  1974.10 Varicella  vaccines,  available
orldwide,  possess  the  single  VZV  or  are  combined  with  the
easles,  mumps,  and  rubella  viruses,  forming  a  tetravalent
accine  (MMRV).6 According  to  Ozaki,  the  preventive  effect
f  varicella  vaccine  was  estimated  at  75%.  In  the  United
tates  it  ranged  between  79%  and  88%  with  the  ﬁrst  dose,
or  all  forms  of  the  disease.6
In  2013,  a  product  development  partnership  under  the
razilian  Ministry  of  Health  involving  the  pharmaceutical
ndustry  enabled  the  production  of  MMRV  at  the  National
nstitute  of  Immunobiological  Technology  (Biomanguinhos)
f  the  Oswaldo  Cruz  Foundation  (Fiocruz,  RJ,  Brazil).  Thus,
niversal  vaccination  against  varicella  began  in  September
013,  in  Brazil,  through  the  National  Immunization  Program
NIP).  A  single  dose  of  MMRV  is  administered  at  the  age  of
5  months;  for  infants  receiving  the  MMR  (measles,  mumps,
nd  rubella),  at  age  12  months.
Universal  vaccination  is  likely  to  change  the  epidemiol-
gy  of  varicella  in  Brazil,  requiring  baseline  data  to  evaluate
he  impact  of  the  varicella  vaccination  program.  This  study
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Table  1  Average  year  mortality  rates  for  varicella  per  100,000  by  age  group  in  Brazilian  regions,  1996--2011.
<1  1--4  5--9  10--14  15--19  20--29  30--39  40--49  50--59  60--69  70--79  >80
South  0.51  0.35  0.06  0.03  0.01  0.02  0.04  0.03  0.03  0.02  0.05  0
Southeast 1.14 0.61  0.15  0.03  0.02  0.01  0.02  0.02  0.02  0.02  0.04  0.05
Midwest 1.38  0.68  0.17  0.04  0.02  0.02  0.03  0.04  0.03  0.07  0.13  0
North 0.83  0.23  0.1  0.03  0.05  0.03  0.08  0.09  0.21  0.34  0.54  0.97
Northeast 0.62  0.18  0.05  0.03  0.02  0.01  0.03  0.04  0.05  0.07  0.14  0.35
Brazil 0.88  0.4  0.1  0.03  0.02  0.02  0.03  0.03  0.04  0.06  0.12  0.18
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the  frequency  of  hospitalizations  for  herpes  zoster  ranges
from  4378,  5084,  and  5151  cases  per  month  in  Brazil  in  the
age  groups  60--69,  70--79,  and  over  80  years  old,  respec-
tively.  The  total  number  of  hospitalizations  associated  with
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nsaims  to  describe  the  frequency  and  seasonal  distribution
of  varicella-associated  deaths,  as  well  as  the  frequency  of
VZV-related  hospitalizations  in  the  pre-vaccination  period  in
Brazil.
Materials and methods
Varicella-associated  mortality  data  and  VZV-associated
hospitalizations  were  gathered  from  the  Informatics  Depart-
ment  of  the  Uniﬁed  Health  System  (DataSUS),  through
the  website  http://www2.datasus.gov.br/DATASUS/index.
php?area=02.  On  the  Health  Information  page,  the  Mortality
section  of  Vital  Statistics  was  accessed  in  order  to  review
varicella-related  deaths.  The  Hospital  Morbidity  section  in
Epidemiological  Information  and  Morbidity  was  accessed
in  order  to  assess  VZV-related  hospitalizations.  Varicella-
related  deaths  were  veriﬁed  according  to  the  International
Classiﬁcation  of  Diseases,  10th  Revision  (ICD-10)  code  B01.
VZV-associated  hospitalizations  were  veriﬁed  according
to  an  uncoded  morbidity  list  (ICD-10).  Varicella  deaths
comprised  the  period  1996--2011,  and  hospitalizations  for
varicella  and  herpes  zoster  from  2008  to  2013  were  stud-
ied.  When  data  collection  was  performed,  the  latest  period
available  for  death  records  was  prior  2011,  and  for  hos-
pitalizations,  before  2013.  Moreover,  in  the  period  prior
to  1996,  the  age-related  data  were  uneven.  The  authors
considered  both  varicella  and  herpes  zoster  for  hospitaliza-
tions  because  DataSUS  does  not  discriminate  hospitalization
records  between  varicella  and  herpes  zoster.  Varicella-
related  deaths  were  evaluated  because  the  disease  is  more
frequent  in  children.
Varicella-speciﬁc  mortality  in  age  groups  was  calcu-
lated  as  the  number  of  varicella  deaths  in  infants  aged
less  than  1  year  ×  100,000/population  less  than  1  year,
and  in  children  aged  1--4  years  ×  100,000/population  aged
1--4  years  in  ﬁve  Brazilian  macro-regions  (North,  North-
east,  South,  Southeast,  and  Midwest).  Population  size  used
in  the  denominators  was  obtained  from  the  Brazilian  Insti-
tute  of  Geography  and  Statistics  (Instituto  Brasileiro  de
Geograﬁa  e  Estatística  [IBGE])  based  on  the  1991,  2000,
and  2010  censuses  and  respective  annual  intercensal  pro-
jections.  Seasonality  of  VZV-associated  hospitalizations  was
evaluated  through  the  averages  and  standard  deviations
of  the  monthly  number  of  VZV-associated  hospitalizations
from  2008  to  2013  in  the  age  groups.  It  was  assumed
that  VZV-associated  hospitalizations  among  infants  aged
under  1 year  and  1--4  years  are  predominantly  related  to
varicella,  while  hospitalizations  among  adults  older  than
F
b5  years  old  are  mainly  caused  by  herpes  zoster.  The
tudy  was  submitted  to  the  Ethics  Committee  of  Oswaldo
ruz  Institute  and  approved  with  reference  number  CAAE
7704214.3.0000.5248.
esults
here  were  2334  varicella-associated  deaths  between  1996
nd  2011  in  Brazil.  From  these,  19.3%  (n  =  450)  were  in
nfants  aged  less  than  one  year,  36%  (n  =  840)  were  in  chil-
ren  aged  1--4  years,  11.7%  (n  =  273)  in  children  aged  5--9
ears,  and  33%  (n  =  771)  in  patients  more  than  9  years  old.
able  1  shows  the  average  mortality  rates  for  varicella  in
ge  groups  in  distinct  Brazilian  regions,  from  1996  to  2011.
n  infants  under  1  year  of  age,  varicella  mortality  rates  vary
n  distinct  Brazilian  regions,  from  0  to  3.2/100,000/year.  In
hildren  aged  1--4  years,  varicella  mortality  rates  vary  from
 to  1.64/100,000/year.  Average  annual  mortality  rates  for
aricella  in  Brazil  from  1996  to  2011  were  0.88/100,000  in
nfants  under  1  year  and  0.40/100,000  in  children  aged  1--4
ears.
The  number  of  VZV-associated  hospitalizations  by  age
roup  in  the  period  before  MMRV  vaccine  introduction  in
razil  from  2008  to  2013  is  represented  in  Fig.  1. The  major-
ty  of  hospitalizations  emerged  in  children  under  9  years  of
ge,  with  peaks  in  the  age  group  1--4  years  and  in  the  elderly
fter  80  years  of  age.  The  present  study  demonstrates  that7
Age category (years)
igure  1  Varicella-zoster  virus  hospitalizations  by  age  groups
efore  tetraviral  vaccine  introduction  in  Brazil,  2008--2013.
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Figure  2  Monthly  averages  of  hospitalizations  for  varicella
in different  age  categories,  showing  a  seasonal  distribution  in
children  (A,  B)  and  no  variation  in  adults  (C,  D).  (A)  Infants  aged
under  1  year.  (B)  Children  aged  1--4  years.  (C)  Adults  aged  65--69
years.  (D)  Adults  aged  75--79  years.
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ZV  was  62,052,  and  varicella-associated  hospitalizations
ad  a  seasonal  distribution  in  children,  peaking  in  November.In  adults  older  than  65  years,  monthly  averages  of  herpes-
oster-associated  hospitalizations  presented  no  variation.
verages  and  standard  deviations  of  monthly  numbers  of
ospitalizations  from  2008  to  2013  are  depicted  in  Fig.  2A--D.
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iscussion
his  study  demonstrated  signiﬁcant  morbidity  and  mortality
rom  varicella  in  Brazil  prior  to  the  introduction  of  MMRV  into
he  NIP.  Data  suggest  that  varicella  should  not  be  considered
s  a  benign  disease,  as  it  presents  frequent  complications.
lthough  the  majority  of  deaths  were  in  children  aged  1--4
ears,  the  mortality  rate  is  higher  in  infants  aged  less  than
 year.  Data  suggest  that  the  risk  of  a  child  dying  from
aricella  is  twice  as  high  for  infants  under  1 year  than  chil-
ren  aged  1--4  years.  However,  the  MMRV  vaccine  in  the
razilian  NIP  is  given  to  children  aged  15  months.  Thus,  vari-
ella  would  not  be  prevented  in  younger  infants.  In  some
ountries  practicing  universal  varicella  vaccination,  the  vac-
ine  is  administered  earlier,  at  12  months  of  age,  as  in  the
nited  States,  Canada,  Japan,  China,  and  Uruguay.6,11--14
mportantly,  the  cohort  of  immunized  children  will  increase
rogressively  over  the  next  years,  putatively  leading  to
educed  VZV  circulation  among  immunized  children,  which
ill  beneﬁt  children  less  than  1  year  old  by  herd  immu-
ity,  as  described  by  Streng  et  al.15 However,  the  potential
eactivation  of  VZV  in  adults  represents  a continuous  repos-
tory  of  wild  strains.  In  this  case,  children  under  15  months
ld  will  be  susceptible  to  acquiring  the  infection.
Although  there  was  a  signiﬁcant  reduction  in  varicella-
ssociated  hospitalizations  in  countries  that  have  adopted
niversal  vaccination,  like  the  United  States,  outbreaks
ave  still  been  reported,  even  among  populations  with  high
ingle-dose  coverage.  In  the  United  States,  the  Advisory
ommittee  on  Immunization  Practices  passed  the  recom-
endation  for  routine  two-dose  varicella  vaccination  in
006,  which  was  10  years  after  the  one-dose  varicella  vac-
ination  program  started  in  the  United  States.  Moreover,
he  second  dose  was  recommended  not  only  for  outbreaks,
ut  also  to  increase  protection  against  varicella.16 Conse-
uences  of  vaccine  failure  are  potentially  serious  due  to  the
ontinuous  transmission  of  wild  VZV  and  the  accumulation
f  susceptible  young  adults.17 Consequently,  the  need  for  a
econd  dose  of  varicella  vaccine  in  some  countries  has  been
onsidered.18 Nevertheless,  the  high  morbidity  and  mortal-
ty  in  children  aged  1--4  years  in  Brazil  demonstrates  the
otential  positive  impacts  of  a  single  MMRV  dose  given  at
he  age  of  15  months.
According  to  Goldman  and  King,19 there  has  been  a  sig-
iﬁcant  increase  in  the  incidence  of  herpes  zoster  over
he  years  following  implementation  of  universal  vaccina-
ion  against  VZV  in  the  United  States,  concomitantly  with
he  decline  in  varicella  incidence.  Therefore,  it  has  been
rgued  that  the  potential  increase  in  the  incidence  of  her-
es  zoster  could  nullify  the  beneﬁts  of  vaccination.19,20 This
ncrease  would  be  related  to  the  low  circulation  of  wild  VZV
n  a  vaccinated  population,  which  represents  a  vaccination
ooster,  increasing  the  immune  response  to  VZV  and  pre-
enting  viral  reactivation  in  the  nervous  system.19,21 Data
rom  the  present  study  provide  a  baseline  for  comparing  the
ost-vaccination  period.
Despite  the  existence  of  vaccination  programs  in  sev-
ral  developed  and  developing  countries,  a  question
emains:  whether  or  not  to  vaccinate  children  against
aricella?
Varicella  in  Brazil  cannot  be  considered  a  benign  disease,
ince  it  is  responsible  for  an  average  of  155  deaths  per  year,
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representing  almost  one  death  every  two  days  by  the  dis-
ease,  generating  an  average  of  34  hospitalizations  per  day.  In
the  population  of  children  aged  1--4  years,  an  average  of  nine
hospitalizations  per  day  by  the  disease  has  been  reported.
This  scenario  leads  the  authors  to  believe  that  varicella  in
developing  countries  --  in  conjunction  with  factors  such  as
poverty,  malnutrition,  and  lack  of  access  to  health  care
--  frequently  requires  hospitalization,  possibly  resulting  in
death.  In  addition,  the  indirect  costs  of  the  disease  must
be  considered,  such  as  parental  work  leave  and  caregiver
expense.  The  estimated  average  cost  of  workday  loss  for  a
mother  with  a  child  under  15  years  old  with  varicella  was
US$  5.90,  in  2004.22
In  must  be  emphasized  that  during  14  years,  varicella  vac-
cination  was  available  in  private  vaccination  clinics  widely
used  by  the  population  of  the  middle  and  upper  classes  in
Brazil.  However,  there  was  circulation  of  wild  VZV  in  this
period,  which  exposed  the  vaccinated  population  to  the
boosters  that  prevented  weaning  of  immunity  after  vacci-
nation.
Varicella  had  always  been  associated  in  the  pre-vaccine
period  to  a  signiﬁcant  number  of  deaths  and  hospitaliza-
tions.  The  introduction  of  MMRV  into  the  Brazilian  NIP
generated  expectations  of  a  positive  impact,  especially  for
children.
Varicella-speciﬁc  mortality  rates  vary  in  different  years.
These  rates  in  infants  under  one  year  are  twice  as  high  as
those  observed  in  children  aged  1--4  years,  although  the
absolute  number  is  greater  in  the  range  of  1--4  years.  This
indicates  that  a  child  under  1  year  has  double  the  risk  of
dying  from  chickenpox  when  compared  to  children  aged  1--4
years.  Varicella-speciﬁc  mortality  rates  are  higher  in  the
Brazilian  Midwest  and  Southeast.  VZV-related  hospitaliza-
tions  have  a  bimodal  distribution,  peaking  in  children  under
9  years  old  and  persons  older  than  80.  There  is  a  seasonal
pattern  in  hospitalizations  for  varicella  in  children,  with  a
higher  monthly  average  from  September  to  November;  this
is  not  observed  in  adults,  which  may  be  related  to  non-
seasonal  VZV-reactivation  associated  with  herpes  zoster.
This  survey  has  some  limitations,  because  it  is  a  ret-
rospective  study  using  secondary  data.  Furthermore,  the
diagnosis  of  varicella  and  herpes  zoster  are  eminently
clinical  and  varicella  was  not  a  reportable  disease  in  all
Brazilian  states  until  September  2013.  Therefore,  it  is
possible  that  the  disease  is  underdiagnosed,  especially  in
country’s  regions  where  access  to  health  care  programs  is
still  precarious.
Because  varicella  in  Brazil  is  a  disease  that  leads  to
almost  one  death  every  two  days  and  because  it  has  a  worse
prognosis  in  developing  countries,  the  authors  conclude  that
universal  varicella  vaccination  is  fully  justiﬁed  in  the  coun-
try.  An  epidemiologic  follow-up  of  breakthrough  varicella
and  herpes  zoster  cases  that  will  possibly  occur  more  often
in  the  coming  years  is  essential,  and  it  is  vital  to  discuss
the  inclusion  of  a  second  dose  of  varicella  vaccine  in  the
Brazilian  NIP.Funding
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